Pratia and KFGN Join Forces


Applied Clinical Trials

Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network. 

For more information, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.